Clinical trial · Observational
Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas
Lung Cancer Incidence in Patients With Type 2 Diabetes and COPD: A Real-World Retrospective Cohort Study Comparing SGLT2 Inhibitors and Sulfonylureas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to learn if a specific diabetes medicine can lower the risk of lung cancer in people with type 2 diabetes and chronic obstructive pulmonary disease (COPD). The main question it aims to answer is: \- Does taking medicines called SGLT2 inhibitors lower the chance of getting lung cancer compared to medicines called sulfonylureas? Researchers will compare the medical records of people taking SGLT2 inhibitors to those taking sulfonylureas to see if the SGLT2 group has fewer cases of lung cancer. Participants will not need to visit a doctor or take new medicines for this study. Researchers will use information from existing medical records to answer the research question.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| COPD (Chronic Obstructive Pulmonary Disease) | — | UNRESOLVED | — |
| Lung Cancer (Diagnosis) | Malignant Lung Neoplasm | CURATED_EXACT | 0.85 |
| Type 2 Diabetes | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DPP4 inhibitors | Drug | — | UNRESOLVED |
| SGLT2 inhibitor | Drug | — | UNRESOLVED |
| Sulfonylureas (SU) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- label
- Treatment group (main)
- description
- Users of SGLT2 inhibitors (for ITT analysis)
- interventionNames
- Drug: SGLT2 inhibitor
- label
- Active control group (main)
- description
- Users of sulfonylureas for ITT analysis
- interventionNames
- Drug: Sulfonylureas (SU)
- label
- Treatment group (S1)
- description
- Users of SGLT2 inhibitors (for ITT analysis)
- interventionNames
- Drug: SGLT2 inhibitor
- label
- Active control group (S1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Adults aged ≥40 years with prior COPD (from 2009) and newly diagnosed diabetes who initiated SU or SGLT2i between January 1, 2014 and December 31, 2023 Exclusion Criteria: * Pre-existing * ESRD * Cancer * Concurrent prescribing of the study drugs at the index date * Exposure to the drugs of interest during the year preceding the index date * Death or cancer incidence within a month In the sensitivity analysis, we are planning to substitute sulfonylurea to DPP4 inhibitors.
References
Publications (0)
Data not yet available